17 January 2018 | News
Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer
Syndax Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications.
The company declared a new clinical partnership with Genentech, a member of the Roche Group.
As part of the collaboration, the two companies will evaluate the combination of Syndax's entinostat, an oral, small molecule, class I HDAC inhibitor, and Genentech's programmed cell death ligand 1 (PD-L1) blocking antibody, atezolizumab (TECENTRIQ®).
The planned Phase Ib/II, open-label, multicenter, randomized trial will enroll patients with metastatic HR+, HER2- breast cancer who have experienced disease progression during or following first-line therapy.
Genentech will be responsible for conducting the trial. The trial will be conducted as part of MORPHEUS, Roche's novel cancer immunotherapy development platform.
This is an adaptive platform that aims to develop combinations of cancer immunotherapies more rapidly and efficiently.
Syndax also has a separate collaboration with Genentech for ENCORE 602, a trial examining safety, tolerability and clinical activity of entinostat in combination with Tecentriq in triple-negative breast cancer.
ENCORE 602 is expected to complete enrollment in the Phase II portion of the trial in the first half of 2018.